Restless legs and menopause: Menopause Connection and Treatment

Restless legs syndrome (RLS) — an urge to move the legs, worse at night — becomes more common in perimenopause. Iron deficiency, low estrogen effects on dopamine, and disrupted sleep architecture all contribute. This page summarizes the menopause link, prevalence, and evidence-based next steps for restless legs and menopause.

What is restless legs and menopause?

Restless legs syndrome (RLS) — an urge to move the legs, worse at night — becomes more common in perimenopause. Iron deficiency, low estrogen effects on dopamine, and disrupted sleep architecture all contribute. Roughly 10 percent of midlife women meet criteria.

Menopause connection

Restless legs syndrome (RLS) is understood as a dopaminergic and iron-storage disorder. Estrogen modulates dopaminergic tone, and midlife iron shifts (heavier perimenopausal bleeding, then reduced absorption) lower ferritin — both mechanisms push RLS onset upward around menopause.

Prevalence data

Roughly one in ten midlife women meets criteria for RLS, with prevalence rising through perimenopause. Symptoms are worst in the evening and at rest and improve with movement.

Estimated monthly search volume for related queries: 1,900/mo (aggregated from public keyword-research tools; indicative of information demand, not clinical prevalence).

When to seek care

Treatment options

Options below are educational summaries of approaches described in NAMS and ACOG guidance for peri- and post-menopausal care. Individual selection depends on medical history, symptom severity, and clinician judgment.

  • Ferritin check — a target above 75 ng/mL is common in RLS practice; oral iron replacement is the first-line adjustment when levels are low.
  • Sleep hygiene — consistent bedtime, cool bedroom, avoiding late caffeine and alcohol.
  • Trigger review — some antihistamines, dopamine antagonists, and antidepressants can provoke or worsen RLS; a clinician-led medication review is warranted.
  • Movement strategies — light stretching, warm baths, and evening walks reduce nightly severity for many patients.
  • Neurology referral or pharmacologic therapy for persistent symptoms after iron correction.

Frequently asked questions

Is restless legs and menopause a symptom of menopause?
Yes. Restless legs syndrome (RLS) — an urge to move the legs, worse at night — becomes more common in perimenopause. Iron deficiency, low estrogen effects on dopamine, and disrupted sleep architecture all contribute. Roughly 10 percent of midlife women meet criteria.
How long does restless legs and menopause last during menopause?
Duration varies. Symptoms tend to be most active during the perimenopausal transition and the first two to five years around the final menstrual period. Many women see gradual improvement in later post-menopause, but a subset experience persistent symptoms that warrant clinical evaluation.
When should I see a healthcare provider about restless legs and menopause?
See a provider if symptoms occur three or more nights per week, disrupt sleep, or worsen over time. Ferritin should be checked (aim above 75 ng/mL). Iron replacement often reduces symptoms significantly before medication is needed.
Does menopausal hormone therapy help restless legs and menopause?
Menopausal hormone therapy is proven for vasomotor symptoms and genitourinary syndrome of menopause. Evidence for its role in restless legs and menopause specifically is more limited and is typically discussed with a clinician when the symptom co-occurs with other moderate-to-severe menopausal symptoms.
Can lifestyle changes reduce restless legs and menopause?
Sleep consolidation, stress management, hydration, and reviewing dietary and medication triggers reduce symptom burden for many women. These measures are inexpensive, low-risk, and worth trying alongside a clinical evaluation for the underlying cause.

Primary medical sources

  1. NAMSThe North American Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
  2. NAMSThe North American Menopause Society. The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. Menopause. 2023;30(6):573-590.
  3. ACOGAmerican College of Obstetricians and Gynecologists. Practice Bulletin: Management of Menopausal Symptoms.

Disclaimer